Hepatoprotective Potential of Madhuca longifolia Extracts:

Preclinical Evidence, Mechanisms and Clinical Research Gaps

Vandana Yadav¹, Ashish William¹, Renu Das², Purnima Baghel²

¹Students, Chouksey School of Pharmacy, CEC, Bilaspur, Chhattisgarh, India.

²Assistant Professor, Chouksey School of Pharmacy, CEC, Bilaspur, Chhattisgarh, India.

*Corresponding Author E-mail: anishc@cecbilaspur.ac.in

ABSTRACT:

Liver disorders constitute a major global health challenge, and the limitations associated with currently available hepatoprotective agents have intensified interest in plant-derived therapeutics. Madhuca longifolia (Sapotaceae), a medicinal tree extensively used in traditional Indian medicine, has been investigated for its protective effects against experimentally induced liver injury. This review critically evaluates the available literature on the hepatoprotective potential of M. longifolia extracts, with particular emphasis on phytochemical composition, preclinical efficacy, proposed mechanisms of action, toxicological considerations, and the current status of clinical research. Preclinical studies consistently demonstrate that extracts derived from the flowers, bark, leaves, and seeds of M. longifolia mitigate hepatotoxicity induced by agents such as paracetamol, carbon tetrachloride, and D-galactosamine. These effects are evidenced by normalization of serum biochemical markers, restoration of antioxidant defenses, and improvement of histopathological features. Mechanistically, hepatoprotection is largely attributed to antioxidant, anti-inflammatory, and membrane-stabilizing properties mediated by flavonoids, phenolic compounds, triterpenoids, and saponins. Despite compelling experimental data, clinical evidence remains extremely limited, with no well-designed randomized controlled trials directly assessing hepatic outcomes in humans. This review highlights critical gaps in standardization, safety evaluation, and clinical validation, and outlines future research directions necessary for the translational development of M. longifolia as a hepatoprotective agent.

KEYWORDS: Madhuca longifolia; Hepatoprotection; Hepatotoxicity; Medicinal plants; Antioxidant activity; Liver injury; Phytotherapy.

1. INTRODUCTION:

The liver is a vital organ responsible for metabolic regulation, detoxification, and maintenance of systemic homeostasis. Exposure to xenobiotics, including pharmaceuticals, environmental toxins, and alcohol, renders the liver particularly susceptible to injury. Drug-induced liver injury and chronic liver diseases remain significant contributors to global morbidity and mortality¹. Although several synthetic hepatoprotective agents are in clinical use, their therapeutic efficacy is often limited by adverse effects and inconsistent outcomes. Consequently, there is growing scientific interest in identifying safer, plant-derived alternatives.

In recent years, herbal medicine has gained substantial global attention and acceptance in both developing and developed countries, largely due to its natural origin and comparatively fewer side effects. Among traditional medicinal plants, the Mahua tree (Madhuca longifolia), belonging to the family Sapotaceae, genus Madhuca, and species longifolia, holds significant cultural, medicinal, and economic importance, particularly among tribal communities in several Indian states, including Odisha, Jharkhand, Chhattisgarh, Andhra Pradesh, Bihar, and West Bengal². M. longifolia is also native to other parts of South Asia, such as Sri Lanka, Myanmar, and Nepal³. The species predominantly grows in marginal and semi-arid regions, commonly found in dry mixed deciduous forests, dry forests, and dry teak forests, and thrives in sandy, shallow, boulder-strewn, clayey, and calcareous soils⁴.

Mahua has long been utilized for medicinal purposes and is increasingly recognized within traditional healthcare systems, including its emerging relevance in Traditional Chinese Medicine (TCM). The flowers of M. longifolia are edible and possess high nutritional value, being rich in sugars, vitamins, proteins, minerals, and fats⁵. Owing to their high sugar content, the flowers are widely used by indigenous tribal populations for preparing various traditional foods and beverages⁶. Volatile oil extracted from the fruits is commonly used in the manufacture of soaps, hair oils, cooking oils, and massage oils, while the inner portion of the fruit is used in cake preparation and the outer part is consumed in raw form³.

Traditional knowledge attributes a wide range of pharmacological properties to the Mahua plant. Its flowers are traditionally used to manage cardiovascular disorders, ear ailments, diabetes, rheumatoid arthritis, and burning sensations, and are also administered in conditions such as piles, sinusitis, and bleeding disorders⁷. Flower juice and seeds are known to support lactation and enhance breast milk production. The bark is traditionally employed in the treatment of rheumatism, diabetes, gum disorders, and burns¹², while the leaves are used to treat various skin conditions, including eczema and burns. Such food plants are valuable not only as sources of nutrition but also as reservoirs of bioactive compounds with potential therapeutic benefits³.

Recent research has further highlighted the role of M. longifolia in advancing Traditional Chinese Medicine by providing molecular and genomic insights into this medicinal species. Understanding the genetic mechanisms underlying its tolerance to low-temperature stress may enable its cultivation in cooler regions of China, thereby supporting sustainable local production and expanding its availability for TCM formulations in subtropical and temperate zones⁸

Madhuca longifolia (Koenig) J.F. Macbr., commonly known as Mahua, is a deciduous tree native to the Indian subcontinent and widely utilized in traditional medicine. Various parts of the plant are traditionally prescribed for inflammatory conditions, metabolic disorders, and hepatic ailments. These ethnomedicinal claims have stimulated extensive experimental research aimed at validating its hepatoprotective properties⁹. Therefore, all of the information on the chemical components, phytochemical applications, and pharmacological characteristics of each part of the mahua plant is included in this review. Therefore, the purpose of this study is to concentrate on the use of mahua as medicine with special light on its hepatoprotative effects.

2. Phytochemical Composition and Extract Variability:

Phytochemical investigations reveal that M. longifolia contains a diverse spectrum of secondary metabolites, including flavonoids, phenolic acids, triterpenoids, sterols, saponins, and long-chain fatty acids. The qualitative and quantitative composition of these constituents varies significantly depending on the plant part, geographical origin, harvesting conditions, and extraction methodology. Flowers and bark are particularly rich in phenolic compounds, whereas seeds predominantly contain lipophilic constituents¹⁰.

Synonyms-Mahua, Mahva, Butter nut tree.

Taxonomy and Nomenclature:

Binomial Name : Madhuca Longifolia

Kingdom : Plantae

Order : Ericaleae

Family : Sapotaceae

Subfamily : Caesalpiniodeae

Tribes : Caesalpinieae

Genus : Madhuca

Species : longifolia

Chemical constituents- Madhuca longofolia are mainly composed of many chemical constituents like phenols, flavonoids etc.^11-14.

Leaves:

Mahua leaves are consists of compounds like quercetin, sitosterols, β-carotene, D-Glucoside, Xanthophyll, stigmasterol, erythrodiol, n-hexacosanol, palmitic acid, myricetin, n-octacosanol, quercetin,3-galactoside, xanthophylls,3β-caproxy,3β-palmitoxy,3-O-β-D-glucoside, β- sitosterol-β-Dglucoside.

Quercetin Erythrodiol

3-galactoside

Bark of mahua plant is composed of α and β amyrin acetates, Ethyl acetates, Ethyl cinnamate, Betulinicacid, α-terpinol, Sesquiterpene alcohol.

Betulinic acid β-amyrin acetate

Ethyl cinnamate

Flowers- Flowers are composed of vitamins like A&C. (Hoffman et al.,1996), many main chemical constituents of mahua flowers i.e quercetin, betulinic acid, tannins, β-amyrin acetate, stigmasterol.

Betulinic acid Stigmasterol

Seeds- seeds are composed of acids like arachidic, oleic, linoleic, aspartic acid, Protobassic acid, iso-leucine, lysine, Myristic acid, palmitic acid & stearic acid, cysteine, α- alanine, glycine, serine, methionine, threonine, lenine, Mi-saponin(A), &Mi-saponin(B), Madlongiside (A, B, C, D).

Aspartic acid protobassic acid

Myristic acid

Fruits-n-hexacosanol, β-sitosterol & 3-β-D-Glucoside, quercetin, dihydro quercetin & α&β amyrin acetates.

β-sitosterol Quercetin

α-amyrin acetate

A major limitation in the existing literature is the lack of standardized extracts and validated chemical markers, which compromises reproducibility and comparability across studies. Recent reviews strongly advocate for the development of chemically characterized extracts to facilitate mechanistic elucidation and translational research.

3. Preclinical Evidence of Hepatoprotective Activity:

3.1 Biochemical and Functional Outcomes:

The hepatoprotective efficacy of M. longifolia has been extensively evaluated in rodent models of chemically induced liver injury. Administration of aqueous, ethanolic, or methanolic extracts significantly attenuates elevations in serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and bilirubin levels induced by paracetamol, carbon tetrachloride, or D-galactosamine. Additionally, treatment restores endogenous antioxidant defenses, including reduced glutathione and antioxidant enzyme activity, while suppressing lipid peroxidation¹⁵.

3.2 Histopathological Findings:

Histological examination of hepatic tissue consistently corroborates biochemical findings. Extract-treated animals exhibit reduced hepatocellular necrosis, steatosis, sinusoidal congestion, and inflammatory infiltration compared with untreated toxic controls. These structural improvements indicate preservation of hepatic architecture and functional integrity.

4. Mechanistic Basis of Hepatoprotection:

The hepatoprotective effects of M. longifolia are primarily attributed to

1. antioxidant and free-radical scavenging activity (phenolics, flavonoids);

2. anti-inflammatory effects (reduced cytokine signaling and leukocyte infiltration);

3. membrane-stabilizing effects that reduce enzyme leakage; and

4. possible modulation of xenobiotic-metabolizing enzymes that blunt formation of reactive metabolites in paracetamol and CCl₄ models.

Flavonoids and phenolic compounds scavenge reactive oxygen species and mitigate oxidative stress, a key mediator of hepatocellular injury. Triterpenoids and saponins are proposed to stabilize cellular membranes and modulate inflammatory signaling pathways, thereby limiting enzyme leakage and tissue damage. Some evidence also suggests modulation of hepatic xenobiotic-metabolizing enzymes, potentially reducing the formation of reactive toxic intermediates¹⁶.

5. Toxicological and Safety Considerations

Available acute toxicity studies suggest that M. longifolia extracts exhibit a relatively favorable safety profile at hepatoprotective doses in experimental animals. However, data on chronic toxicity, reproductive toxicity, genotoxicity, and pharmacokinetics remain insufficient. Given the traditional consumption of Mahua-derived fermented products, systematic evaluation of long-term exposure and interactions with alcohol and other hepatotoxins is warranted. Regulatory advancement will require comprehensive toxicological assessment conducted in accordance with international guidelines¹⁷.

6. Clinical Evidence and Translational Limitations:

Despite substantial preclinical support, clinical evidence for the hepatoprotective efficacy of M. longifolia remains scarce. To date, no randomized controlled trials have evaluated standardized M. longifolia extracts using validated hepatic endpoints. Existing human data are largely observational, derived from epidemiological studies among tribal populations consuming Mahua-based products, and do not permit causal inference regarding liver protection. Recent systematic reviews uniformly identify the absence of clinical trials as a critical barrier to therapeutic translation¹⁸.

Table 1. Preclinical studies evaluating the hepatoprotective effects of Madhuca longifolia

Plant part	Species / Strain	Hepatotoxicity model	Extract type	Dose (mg/ kg, p.o.)	Key endpoints assessed	Major findings	Reference
Flowers	Wistar rats	Paracetamol-induced hepatotoxicity	Methanolic extract	200, 400	AST, ALT, ALP, bilirubin, liver histology	Significant reduction in serum liver enzymes; improved hepatic architecture	9
Flowers	Albino rats	CCl₄-induced hepatotoxicity	Ethanolic extract	250, 500	AST, ALT, ALP, lipid peroxidation, histology	Dose-dependent hepatoprotection and antioxidant effect	11
Bark	Wistar rats	Paracetamol-induced hepatotoxicity	70% ethanolic extract	100, 300	AST, ALT, ALP, GSH, SOD, CAT	Restoration of antioxidant enzymes; reduced oxidative stress	12
Leaves	Swiss albino mice	CCl₄-induced hepatotoxicity	Aqueous extract	200	Serum enzymes, histopathology	Moderate hepatoprotective effect; reduced necrosis	15
Seeds	Wistar rats	D-galactosamine-induced hepatotoxicity	Methanolic extract	250	AST, ALT, TNF-α, histology	Anti-inflammatory and hepatoprotective effects	16
Flowers	Wistar rats	Alcohol-induced hepatotoxicity	Hydroalcoholic extract	300	ALT, AST, lipid peroxidation	Partial protection against ethanol-induced oxidative injury	17
Bark	Albino rats	Paracetamol-induced hepatotoxicity	Aqueous extract	400	Serum markers, histology	Hepatic enzyme normalization; tissue regeneration	18

7. Research Gaps and Future Directions:

Key gaps include lack of standardized extract(s) and marker-based quality control, insufficient mechanistic clarity at the molecular level, limited toxicology (especially chronic and reproductive studies), and the near-total absence of randomized human trials with liver endpoints. Future research should prioritize the development of standardized, chemically defined extracts and the identification of bioactive marker compounds. Rigorous pharmacokinetic and toxicological evaluations are essential prerequisites for clinical investigation. Early-phase clinical trials should employ robust study designs, clearly defined inclusion criteria, and clinically relevant hepatic biomarkers. Such efforts are necessary to bridge the gap between traditional use, experimental validation, and evidence-based clinical application. To move toward clinical application, following actions can be recommended:

1. Selection and chemical standardization of a lead extract (with 1–2 defined marker compounds);

2. GLP toxicology and ADME/pharmacokinetic profiling;

3. A phase I safety/tolerability study in healthy volunteers; and

4. A small, biomarker-driven phase II randomized, placebo-controlled trial in subjects with a well-defined model of liver injury (for example, drug-induced mild liver enzyme elevation or nonalcoholic fatty liver disease with defined endpoints such as ALT change, imaging, and surrogate oxidative-stress biomarkers).

Parallel work should isolate and test candidate active constituents to enable mechanism-based drug development. Recent reviews have made similar roadmaps [Yasmin S; Dubey I].

8. CONCLUSION:

Experimental evidence strongly supports the hepatoprotective potential of Madhuca longifolia extracts in preclinical models of liver injury. These effects are mediated through antioxidant, anti-inflammatory, and cytoprotective mechanisms. However, the absence of high-quality clinical trials precludes definitive conclusions regarding clinical efficacy. Systematic translational research is required to establish M. longifolia as a scientifically validated hepatoprotective agent.

9. REFERENCES:

1. Simon JP, Evan Prince S. Aqueous leaves extract of Madhuca longifolia attenuate diclofenac‐induced hepatotoxicity: Impact on oxidative stress, inflammation, and cytokines. Journal of cellular biochemistry. 2018 Jul;119(7):6125-35.

2. Behera S, Ray RC, Swain MR, Mohanty RC, Biswal AK. Traditional and current knowledge on the utilization of mahua (Madhuca latifolia L.) flowers by the Santhal tribe in Similipal biosphere reserve, Odisha, India. Annals of Tropical Research. 2016 Jul 1;38(1):94-104.

3. Saluja MS, Sangameswaran B, Hura IS, Ajay Sharma AS, Gupta SK, Chaturvedi M. In vitro cytotoxic activity of leaves of Madhuca longifolia against Ehrlich Ascites Carcinoma (EAC) cell lines.

4. Sinha J, Singh V, Singh J, Rai AK. Phytochemistry, ethnomedical uses and future prospects of Mahua (Madhuca longifolia) as a food: a review. J Nutr Food Sci. 2017;7(573):2.

5. Johar V, Kumar R. Mahua: A versatile Indian tree species. Journal of Pharmacognosy and Phytochemistry. 2020;9(6):1926-31.

6. Chandra D. Analgesic effect of aqueous and alcoholic extracts of Madhuka Longifolia (Koeing). Indian Journal of Pharmacology. 2001 Mar 1;33(2):108-11.

7. Kokate CK, Purohit AP, Gokhale SB. Text book of Pharmacognosy. Pune: Nirali Prakashan. 2003;8(66):500-524.

8. Wang S, Lin H, Ye S, Jiao Z, Chen Z, Ma Y, Zhang L. High-quality chromosome-level genomic insights into molecular adaptation to low-temperature stress in Madhuca longifolia in southern subtropical China. BMC genomics. 2024 Sep 18;25(1):877.

9. Umadevi M, Maheswari C, Jothi R, Paleti SK, Reddy YS, Narayanan RV. Hepatoprotective Activity of Flowers of Madhuca longifolia (Koen.) Macbr. against paracetamol-induced hepatotoxicity. Research Journal of Pharmacy and Technology. 2011; 4(2): 259-62.

10. Devi N, Sangeetha R. Madhuca longifolia (Sapotaceae): A review of its phytochemical and pharmacological profile. Int. J. Pharmacogen. Biosci. 2016; 7(4): 106-14.

11. Shukla S, Verma S, Wal P. Comprehensive Evaluation of Madhuca longifolia: Morphological, Phytochemical, and Pharmacological Perspectives: A Research. Library of Progress-Library Science, Information Technology & Computer. 2024 Jul 20; 44(4).

12. Khare P, Kishore K, Sharma DK. Medicinal uses, Phytochemistry and Pharmacological profile of Madhuca longifolia. Asian Journal of Pharmacy and Pharmacology. 2018; 4(5): 570-81.

13. Kendre N, Wakte P. A review on Phytochemicals and biological attributes of Madhuca longifolia. Asian J Pharm Pharmacol. 2021;7:74-84.

14. Yadav P, Singh D, Mallik A, Nayak S. Madhuca longifolia (Sapotaceae), a review of its traditional uses, phytochemistry and pharmacology. Int J Biomed Res. 2012; 3(7): 291-305.

15. Kumar A, Singh BK, Trivedi N, Aggarwal A. Madhuca longifolia-a review. An International Journal of Pharmacological Research 2015; 1(2): 75-91.

16. Kumar A. A review on Madhuca longifolia. Research in Pharmacy and Health Sciences. 2016; 2(3): 187-95.

17. Odili VU, Akpe AI, Arigbe-Osula ME, Igbinaduwa PO. Antioxidant and hepatoprotective activity of Madhuca longifolia (koenig) bark against CCl4-induced hepatic injury in rats: In vitro and in vivo studies. Res J Pharm Biol Chem Sci. 2010; 1(1): 1-10.

18. Roy SP, Shirode D, Patel T, Shastry CS, Gheewala N, Sonara G, et al. Antioxidant and hepatoprotective activity of Madhuca longifolia (Koenig) bark against CCl4-induced hepatic injury in rats. Biomed Res. 2010; 1(1):1-10.

Received on 10.03.2026 Revised on 02.04.2026

Accepted on 22.04.2026 Published on 08.07.2026

Available online from July 13, 2026

Res. J. Pharmacognosy and Phytochem. 2026; 18(3):295-299.

DOI: 10.52711/0975-4385.2026.00042

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.